The FDA Just Changed the Peptide Conversation: Here’s What Happened

Something significant just happened in the world of peptides.

On July 23–24, the FDA’s Pharmacy Compounding Advisory Committee considered seven widely discussed peptides and voted in favor of six: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while rejecting DSIP (emideltide).

But these votes are widely misunderstood.

In this Energy Code Deep Dive, Dr. Mike Belkowski breaks down what the committee actually voted on, why a YES vote is not FDA drug approval, and the debate that divided the committee: should promising but under-studied peptides remain largely in the gray market, or could regulated pharmacy compounding provide a safer path?

We explore the harm-reduction argument behind the YES votes, the FDA scientists’ objections, concerns surrounding human evidence, product consistency and immunogenicity, why DSIP failed to clear the bar, and what happens next.

This isn't the finish line for peptides. But it could represent a major turning point in how peptide medicine is researched, regulated, and ultimately accessed.

(Educational content only, not medical advice.)

-

Key Quotes From Dr. Mike:

“Six of the seven (peptides) got a thumbs up. One got rejected.”

“A yes vote didn't mean the FDA is declaring the peptide safe and effective.”

“The yes side is saying, ‘Meet people where they are and add safety guardrails.’”